| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
MB-07729 targets fructose-1,6-bisphosphatase (FBPase), a key enzyme in the gluconeogenesis pathway. It acts as a non-competitive inhibitor. By inhibiting FBPase, it reduces the production of glucose from non-carbohydrate precursors, thereby lowering blood glucose levels. This makes it a potential therapeutic target for type 2 diabetes.
|
|---|---|
| ln Vitro |
In vitro, MB-07729 demonstrates potent inhibition of FBPase. Its IC50 values are 31 nM for the human enzyme, 121 nM for the monkey enzyme, and 189 nM for the rat enzyme. This potent inhibition is confirmed in enzyme assays where it reduces the production of fructose-6-phosphate from fructose-1,6-bisphosphate.
|
| ln Vivo |
In vivo, MB-07729 is used as a research tool to study the role of FBPase in glucose homeostasis. By inhibiting FBPase, it lowers blood glucose levels in animal models. It is used to explore the therapeutic potential of FBPase inhibition for the treatment of type 2 diabetes. Its efficacy has been demonstrated in preclinical studies.
|
| Enzyme Assay |
The in vitro enzyme assay for MB-07729 involves measuring the activity of FBPase. The enzyme is incubated with its substrate, fructose-1,6-bisphosphate, in the presence of varying concentrations of the compound. The production of fructose-6-phosphate is measured, typically by a coupled enzyme assay, and the IC50 is calculated from the inhibition curve.
|
| Cell Assay |
In vitro cell culture studies for MB-07729 utilize hepatocytes or other cells that express FBPase. Cells are treated with the compound, and glucose production is measured. The effect on gluconeogenesis is assessed by measuring the conversion of labeled precursors to glucose. The compound's effect on cell viability and metabolism can also be studied.
|
| Animal Protocol |
In vivo animal experiments for MB-07729 are performed in rodent models of type 2 diabetes, such as the db/db mouse or the high-fat diet-fed mouse. The compound is administered orally or intraperitoneally, and its effect on blood glucose levels is measured. An oral glucose tolerance test (OGTT) can be performed to assess its effect on glucose homeostasis. Hepatic glucose production can be measured.
|
| ADME/Pharmacokinetics |
MB-07729 has a molecular formula of C12H15N2O5PS and a molecular weight of 330.3 g/mol. It is a solid compound that is soluble in DMSO. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions. For in vivo studies, it is formulated in suitable vehicles.
|
| Toxicity/Toxicokinetics |
Toxicological data for MB-07729 are limited, as it is a research compound. It is not intended for human use. Comprehensive toxicity studies have not been reported. Standard safety precautions for handling chemical reagents should be followed. Its potent FBPase inhibition suggests it could have significant effects on glucose metabolism.
|
| Additional Infomation |
MB-07729 is a research compound with no clinical approval. It is a valuable tool for studying FBPase biology and the role of gluconeogenesis in glucose homeostasis. It is used in drug discovery programs to explore the therapeutic potential of FBPase inhibition for the treatment of type 2 diabetes.
|
| Molecular Formula |
C12H15N2O5PS
|
|---|---|
| Molecular Weight |
330.30
|
| Exact Mass |
330.044
|
| CAS # |
882755-95-5
|
| PubChem CID |
24770594
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.598
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)C(C1SC(=NC=1C1OC(P(=O)(O)O)=CC=1)N)=O
|
| InChi Key |
OQFMQCXGUUIUAO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H15N2O5PS/c1-12(2,3)10(15)9-8(14-11(13)21-9)6-4-5-7(19-6)20(16,17)18/h4-5H,1-3H3,(H2,13,14)(H2,16,17,18)
|
| Chemical Name |
[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]phosphonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0276 mL | 15.1378 mL | 30.2755 mL | |
| 5 mM | 0.6055 mL | 3.0276 mL | 6.0551 mL | |
| 10 mM | 0.3028 mL | 1.5138 mL | 3.0276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
